Search

Your search keyword '"Laura Armengol-Debeir"' showing total 24 results
Start Over Author "Laura Armengol-Debeir"
24 results on '"Laura Armengol-Debeir"'

1. Incidence, prevalence and clinical presentation of inflammatory bowel diseases in Northern France: a 30-year population-based studyResearch in context

Author

Hélène Sarter, Thibaut Crétin, Guillaume Savoye, Mathurin Fumery, Ariane Leroyer, Luc Dauchet, Thierry Paupard, Hugues Coevoet, Pauline Wils, Nicolas Richard, Dominique Turck, Delphine Ley, Corinne Gower-Rousseau, Eric Agoute, Najib Al Ghossaini, Raied Al Hameedi, Myriam Al Khatib, Saria Al Turk, Jean-Marie Andre, Matthieu Antoine, Michel Antonietti, Amar Aouakli, Laura Armengol-Debeir, Ibrahim Aroichane, Fadi Assi, Eric Auxenfants, Alina Avram, Kassem Azzouzi, Damyan Bankovski, Bernard Barbry, Nicolas Bardoux, Philippe Baron, Anne Baudet, Pauline Bayart, Brice Bazin, Arash Bebahani, Jean-Pierre Becqwort, Houssem Ben Ali, Emmanuel Ben Soussan, Coralie Benard, Vincent Benet, Corinne Benguigui, Abdeslam Bental, Sara Bentaleb-Bellati, Isabelle Berkelmans, Jacques Bernet, Karine Bernou, Nathalie Bertiaux-Vandaele, Pauline Bertot, Valérie Bertrand, Emilie Biloud, Nathalie Biron, Benjamin Bismuth, Cyril Blanchard, Maurice Bleuez, Fabienne Blondel, Valérie Blondin, Marius Bobula, Philippe Bohont, Eléonore Boivin, Vanessa Bon Djemah, Eric Boniface, Philippe Bonniere, Pierre Bonvarlet, Arnaud Boruchowicz, Raoul Bostvironnois, Médina Boualit, Ahlem Bouazza, Bruno Bouche, Christian Boudailler, Claude Bourgeaux, Morgane Bourgeois-Fumery, Arnaud Bourguet, Agnès Bourienne, Hamza Boutaleb, Alexis Bouthors, Julien Branche, Franck Brazier, Marie Bridenne, Hélène Brihier, Laura Bril, Philippe Bulois, Pierre Burgiere, Joël Butel, Jean-Yves Canva, Valérie Canva-Delcambre, Florence Cardot, Sandrine Carette, Pierre Carpentier, Michel Cassagnou, Jean-François Cassar, François Castex, Pascale Catala, Stéphane Cattan, Sylviane Catteau, Bernard Caujolle, Gérard Cayron, Catherine Chandelier, Cloé Charpentier, Marthe Chavance-Thelu, Agathe Cheny, Dinu Chirita, Antoine Choteau, Jean-François Claerbout, Pierre-Yves Clergue, Gil Cohen, Marie Colin, Régis Collet, Jean-Frédéric Colombel, Stéphanie Coopman, Lucie Cordiez, Antoine Cortot, Jean Corvisart, Frédéric Couttenier, Jean-François Crinquette, Valérie Crombe, Abdelhakim Daoudi, Vincent Dapvril, Thierry Davion, Sébastien Decoster, Laurent Defontaine, Nicolas Degrave, Aurélien Dejaeger, Richard Delcenserie, Marine Deleplanque, Dorothée Delesalle, Olivier Delette, Thierry Delgrange, Laurence Delhoustal, Jean-Stéphane Delmotte, Sabri Demmane, Guy Deregnaucourt, Constance Deschepper, Jean-Pierre Desechalliers, Patrick Desmet, Pierre Desreumaux, Gérard Desseaux, Philippe Desurmont, Alain Devienne, Eve Devouge, Alex Devroux, Arnaud Dewailly, Sébastien Dharancy, Aude Di Fiore, Emmanuel Diaz, Djamal-Dine Djeddi, Rachid Djedir, Wissam Doleh, Marie-Laure Dreher-Duwat, Richard Dubois, Clothilde Duburque, Frédéric Ducrot, Philippe Ducrotte, André Dufilho, Christian Duhamel, Caroline Dumant-Forest, Jean-Louis Dupas, Frédéric Dupont, Yves Duranton, Arnaud Duriez, Nicolas Duveau, Mohammadi El Farisi, Khalil El Hachkar, Caroline Elie, Marie-Claire Elie-Legrand, Matthieu Eoche, Essmaeel Essmaeel, Dominique Evrard, Jean-Paul Evrard, Armelle Fatome, Karima Fellah-Sekkai, Bernard Filoche, Laurent Finet, Mathilde Flahaut, Camille Flamme, David Foissey, Peggy Fournier, Philippe Foutrein, Marie-Christine Foutrein-Comes, Thierry Frere, Julie Galand, Philippe Gallais, Claudine Gamblin, Serge Ganga, Romain Gerard, Guillaume Geslin, Yves Gheyssens, Salah Ghrib, Thierry Gilbert, Bénédicte Gillet, Denis Godart, Jean-Michel Godchaux, Guetty Goeguebeur, Odile Goria, Frédéric Gottrand, Philippe Gower, Lucien Grados, Brigitte Grandmaison, Marion Groux, Claire Guedon, Loïc Guerbeau, Mathilde Gueroult-Dero, Jean-François Guillard, Laurence Guillem, François Guillemot, Dominique Guimber, Baya Haddouche, Vincent Hautefeuille, Philippe Hecketsweiller, Geneviève Hecquet, Jean-Pierre Hedde, Hassina Hellal, Pierre-Emmanuel Henneresse, Michel Heraud, Sophie Herve, Bruno Heyman, Patrick Hochain, Philippe Houcke, Lucie Houssin-Baillly, Bruno Huguenin, Silviu Iobagiu, Shata Istanboli, Alexsandar Ivanovic, Isabelle Iwanicki-Caron, Eric Janicki, Marine Jarry, Charlotte Jean Bart, Claude Jonas, Julia Jougon, Anne Jouvenet, Naeim Kassar, Fadi Katherin, Alfred Kerleveo, Ali Khachfe, Alfred Kiriakos, Jean Kiriakos, Olivier Klein, Matthieu Kohut, Richard Kornhauser, Demetrios Koutsomanis, Jean-Eric Laberenne, Eric Lacotte, Guy Laffineur, Marine Lagarde, Anouck Lahaye, Arnaud Lalanne, Ambroise Lalieu, Pierre Lannoy, José Lapchin, Michel Laprand, Denis Laude, Christian Le Couteulx, Charles Le Goffic, Alain Le Grix, Jean-Philippe Le Mouel, Pauline Le Roy, Rachida Leblanc, Paul Lecieux, Stéphane Lecleire, Nathalie Leclerc, Jean Ledent, Jean Lefebvre, Pascale Lefilliatre, Céline Legrand, Patrick Lelong, Bernard Leluyer, Caroline Lemaitre, Lucie Lepileur, Antoine Leplat, Elodie Lepoutre-Dujardin, Gabriel Leppeut, Henri Leroi, Maryvonne Leroy, Benoît Lesage, Jocelyn Lesage, Xavier Lesage, Isabelle Lescanne-Darchis, Dominique Lescut, Bruno Leurent, Michel Lhermie, Louise Libier, Bernard Lisambert, Isabelle Loge, Julien Loreau, Alexandre Louvet, Joséphine Lozinguez, Henri Lubrez, Damien Lucidarme, Jean-Jacques Lugand, Olivier Macaigne, Denis Maetz, Dominique Maillard, Hubert Mancheron, Olivia Manolache, Anne-Bérengère Marks-Brunel, Charline Marre, Raymond Marti, Eric Marzloff, Philippe Mathurin, Jacques Mauillon, Vincent Maunoury, Jean-Luc Maupas, Michèle-Ange Medam Djomo, Chloé Melchior, Ziad Melki, B. Mesnard, Patrice Metayer, Lofti Methari, Franck Meurisse, Laurent Michaud, Patricia Modaine, Angélique Monthe, Loïk Morel, Mathilde Morin, Pierre-Eugène Mortier, Perrine Mortreux, Olivier Mouterde, Nicolas Mozziconaci, Jean Mudry, Maria Nachuri, Minh Dung Ngo, Eric N'guyen Khac, Bertrand Notteghem, Vincent Ollevier, Atika Ouraghi, Barriza Oussadou, Dominique Ouvry, Bernard Paillot, Claire Painchart, Nicole Panien-Claudot, Christian Paoletti, Arsène Papazian, Bruno Parent, Jean-Claude Paris, Philippe Patrier, Bernard Pauwels, Mathieu Pauwels, Richard Petit, Muriel Piat, Sandrine Piotte, Christophe Plane, Bernard Plouvier, Eric Pollet, Pierre Pommelet, Daniela Pop, Charlotte Pordes, Gérard Pouchain, Philippe Prades, Jean-Christophe Prevost, Manon Pruit, Gilles Quartier, Anne-Marie Queuniet, Jean-François Quinton, Alain Rabache, Gilles Raclot, Sébastien Ratajczyk, Nicole Reix, Thibaud Renaut-Vantroys, Marine Revillion, Ghassan Riachi, Clémentine Riault, Cécile Richez, Benoît Rimbert, Philippe Robinson, Juan Daniel Rodriguez, Jean Roger, Jean-Marc Roux, Alain Rudelli, Clémence Saingier, Patrick Schlossberg, David Sefrioui, Michel Segrestin, David Seguy, Célik Seminur, François Sevenet, Jean Silvie, Claire Spyckerelle, Nathalie Talbodec, Noémie Tavernier, Henriette Tchandeu, Aurore Techy, Jean-Luc Thelu, Henri Thiebault, Jean-Marie Thorel, Christophe Thuillier, Guillaume Tielman, Manuella Tode, Jean Tonnel, Jean-Yves Touchais, Audrey Toulemonde-Huguet, Pierre Toumelin, Yvan Touze, Léa Tran, Jean-Luc Tranvouez, Nadia Triki, Justine Turpin, Eric Vaillant, Claude Valmage, Dominique Vanco, Nathalie Vandaele-Bertiaux, Hélène Vandamme, Elise Vander Eeken, Etienne Vanderbercq, Philippe Vandermollen, Philippe Vandevenne, Lionel Vandeville, Alain Vandewalle, Jean-Pierre Vanhoove, Audrey Vanrenterghem, Charlotte Vanveuren, Iona Vasies, Guy Verbiese, Juliette Verlynde, Philippe Vermelle, Christine Verne, Gwenola Vernier-Massouille, Perrine Vezelier-Cocq, Juliette Viart, Benoît Vigneron, Marc Vincendet, Jacques Viot, Y.M. Voiment, Jean-Yves Wallez, Michel Wantier, Faustine Wartel, Jean-Christian Weber, Jean-Louis Willocquet, Nathalie Wizla, Eric Wolschies, Tajiogue Yimfor, Oana Zahara, Alberto Zalar, Sonia Zaoui, and Anne Zellweger

Subjects
Inflammatory bowel disease, Incidence, Prevalence, Population-based registry, Crohn’s disease, Ulcerative colitis, Public aspects of medicine, RA1-1270
Abstract

Summary: Background: In industrialized countries, the incidence of inflammatory bowel disease (IBD) appears stabilized. This study examined the incidence and phenotype of IBD in Northern France over a 30-year period. Methods: Including all IBD patients recorded in the EPIMAD population-based registry from 1988 to 2017 in Northern France, we described the incidence and clinical presentation of IBD according to age, sex and time. Findings: A total of 22,879 incident IBD cases were documented (59% (n = 13,445) of Crohn’s disease (CD), 38% (n = 8803) of ulcerative colitis (UC), 3% (n = 631) of IBD unclassified (IBDU)). Over the study period, incidence of IBD, CD and UC was 12.7, 7.2 and 5.1 per 105 person-years, respectively. The incidence of CD increased from 5.1/105 in 1988–1990 to 7.9/105 in 2015–2017 (annual percent change (APC): +1.9%, p

Published
2024
Full Text
View/download PDF

2. Is abnormal 25 g fructose breath test a predictor of symptomatic response to a low fructose diet in irritable bowel syndrome?

Author

Mathilde Maccarone, Estelle Houivet, Charlotte Desprez, Laura Armengol Debeir, Laura Bril, Philippe Ducrotté, Chloé Melchior, Emilie Grout, Guillaume Gourcerol, Anne-Marie Leroi, Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Normandie Université (NU), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Service de physiologie digestive, urinaire, respiratoire et de l'exercice [CHU Rouen], Centre d'Investigation Clinique [CHU Rouen] (CIC Rouen), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de biostatistiques [CHU Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Hôpital Charles Nicolle [Rouen], CHU Rouen, and CCSD, Accord Elsevier

Subjects
0301 basic medicine, Male, Fructose malabsorption, Critical Care and Intensive Care Medicine, Gastroenterology, Severity of Illness Index, Cohort Studies, chemistry.chemical_compound, 0302 clinical medicine, [SDV.BBM.BC] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM], Irritable bowel syndrome, Nutrition and Dietetics, medicine.diagnostic_test, digestive, oral, and skin physiology, Low fructose diet, Middle Aged, 3. Good health, Fructose breath test, Breath Tests, Positive test result, [SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Female, France, Adult, medicine.medical_specialty, Adolescent, 030209 endocrinology & metabolism, Fructose, 03 medical and health sciences, Young Adult, Predictive Value of Tests, Internal medicine, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], medicine, Humans, [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM], Aged, Breath test, 030109 nutrition & dietetics, business.industry, Rome iii, medicine.disease, Diet, Clinical trial, [SDV.AEN] Life Sciences [q-bio]/Food and Nutrition, chemistry, Irritable bowel syndrome-symptom severity score, business, Predictive factor, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
Abstract

Summary Background Fructose malabsorption may trigger gastrointestinal symptoms in irritable bowel syndrome patients and a low fructose diet seems to improve digestive symptoms. Aim The aim of our study was to determine whether fructose malabsorption detected by a 25g fructose breath test could be a predictor of the efficacy of a low fructose diet. Methods 88 patients (73 women, median age, 45.5 years, range 18–69) with irritable bowel syndrome according to Rome III criteria were included in this prospective, controlled study. All 88 patients had a 25 g fructose breath test; 37 had a positive test result defining fructose malabsorption. All 88 patients followed a low fructose diet for 2 weeks, blinded to their test results. Patients filled self validated-questionnaires before and at the end of the dietary period. The main outcome measurement was the Irritable Bowel Syndrome-Symptom Severity Score. Results Irritable Bowel Syndrome-Symptom Severity Score significantly decreased in fructose absorbers and fructose malabsorbers after a low fructose diet (−68.0 [−137; 0] versus −73.5 [−173; −11.5]) with no difference according to fructose breath test result (adjusted P = 0.984). Conclusion A positive 25 g fructose breath test is not a predictor of the efficacy of a low fructose diet in irritable bowel syndrome. Registered clinical trial www.clinicaltrials.gov ( NCT02188680 ).

Published
2020
Full Text
View/download PDF

3. Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients

Author

Constance, Chapuis-Biron, Anne, Bourrier, Maria, Nachury, Stéphane, Nancey, Yoram, Bouhnik, Mélanie, Serrero, Laura, Armengol-Debeir, Anthony, Buisson, My-Linh, Tran-Minh, Camille, Zallot, Mathurin, Fumery, Guillaume, Bouguen, Vered, Abitbol, Stéphanie, Viennot, Elise, Chanteloup, Sylvie, Rajca, Nina, Dib, Anne-Laure, Parmentier, Laurent, Peyrin-Biroulet, Lucine, Vuitton, Laurent, Siproudhis, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Lille, Hôpital Nord [CHU - APHM], CHU Rouen, Normandie Université (NU), Centre Hospitalier Universitaire de Nancy (CHU Nancy), CHU Amiens-Picardie, CHU Pontchaillou [Rennes], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), and Association Francois Aupetit (AFA), France

Subjects
Adult, Male, medicine.medical_specialty, Fistula, [SDV]Life Sciences [q-bio], Physical examination, Antibodies, Monoclonal, Humanized, Vedolizumab, Cohort Studies, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, Recurrence, Internal medicine, medicine, Animals, Humans, Rectal Fistula, Pharmacology (medical), 030212 general & internal medicine, Young adult, Prospective cohort study, Anus Diseases, Hepatology, medicine.diagnostic_test, business.industry, Gastroenterology, Odds ratio, Middle Aged, medicine.disease, 3. Good health, Treatment Outcome, Cohort, Female, 030211 gastroenterology & hepatology, France, business, Perianal Glands, Cohort study, medicine.drug
Abstract

Background The management of Crohn's disease patients with perianal lesions and anti-TNF failure is challenging. Aims To assess the effectiveness of vedolizumab in perianal Crohn's disease and the predictors of success in a real-life cohort. Methods We conducted a nationwide multicentre cohort study in patients with perianal Crohn's disease who received vedolizumab. In patients with active perianal Crohn's disease, the success of vedolizumab was defined by clinical success (no draining fistula at clinical examination and no anal ulcers for primary lesions) at 6 months without medical or surgical treatment for perianal Crohn's disease. Logistic regression analyses were performed to identify predictors of success. In patients with inactive perianal Crohn's disease, recurrence was defined by the occurrence of lesions and/or the need for medical or surgical treatments. Results One hundred and fifty-one patients were included. Among them 102 patients had active perianal disease, 33 (32.4%) males, mean age 39.8 years, mean Crohn's disease duration 14.6 years; 101 (99%) had received at least one anti-TNF. The median follow-up time was 52 weeks. Sixty-eight per cent of patients discontinued therapy after a median time of 33 weeks. Vedolizumab success was reached in 23/102 (22.5%). Among patients with setons at initiation, 9/61(15%) had a successful removal. In multivariable analysis, factors associated with success were the number of prior biologic agents (≥3, odds ratio, OR: 0.20, 95% CI 0.04-0.98) and no antibiotics at initiation (OR: 4.76, 95% CI 1.25-18.19). In 49 patients with inactive perianal Crohn's disease, perianal disease recurred in 15/49 (30.6%), 11/49 (22.4%) needed dedicated treatments. Median time to recurrence was 22 weeks. Conclusions We identified a low rate of success of vedolizumab in patients with active perianal Crohn's disease, and nearly one third of patients with inactive perianal Crohn's disease had perianal recurrence. Further evaluation is warranted in prospective studies.

Published
2020
Full Text
View/download PDF

4. Dramatic Increase in Incidence of Ulcerative Colitis and Crohn's Disease (1988–2011): A Population-Based Study of French Adolescents

Author

Silvia Ghione, Hélène Sarter, Mathurin Fumery, Laura Armengol-Debeir, Guillaume Savoye, Delphine Ley, Claire Spyckerelle, Benjamin Pariente, Laurent Peyrin-Biroulet, Dominique Turck, Corinne Gower-Rousseau, J M Andre, M Antonietti, A Aouakli, A Armand, I Aroichane, F Assi, J P Aubet, E Auxenfants, F Ayafi-Ramelot, D Bankovski, B Barbry, N Bardoux, P Baron, A Baudet, B Bazin, A Bebahani, J P Becqwort, V Benet, H Benali, C Benguigui, Ben E Soussan, A Bental, I Berkelmans, J Bernet, K Bernou, C Bernou-Dron, P Bertot, N Bertiaux-Vandaële, V Bertrand, E Billoud, N Biron, B Bismuth, M Bleuet, F Blondel, V Blondin, P Bohon, E Boniface, P Bonnière, E Bonvarlet, P Bonvarlet, A Boruchowicz, R Bostvironnois, M Boualit, B Bouche, C Boudaillez, C Bourgeaux, M Bourgeois, A Bourguet, A Bourienne, J Branche, G Bray, F Brazier, P Breban, H Brihier, V Brung-Lefebvre, P Bulois, P Burgiere, J Butel, J Y Canva, V Canva-Delcambre, J P Capron, F Cardot, P Carpentier, E Cartier, J F Cassar, M Cassagnou, J F Castex, P Catala, S Cattan, S Catteau, B Caujolle, G Cayron, C Chandelier, M Chantre, J Charles, T Charneau, M Chavance-Thelu, D Chirita, A Choteau, J F Claerbout, P Y Clergue, H Coevoet, G Cohen, R Collet, J F Colombel, S Coopman, J Corvisart, A Cortot, F Couttenier, J F Crinquette, V Crombe, I Dadamessi, V Dapvril, T Davion, S Dautreme, J Debas, N Degrave, F Dehont, C Delatre, R Delcenserie, O Delette, T Delgrange, L Delhoustal, J S Delmotte, S Demmane, G Deregnaucourt, P Descombes, J P Desechalliers, P Desmet, P Desreumaux, G Desseaux, P Desurmont, A Devienne, E Devouge, M Devred, A Devroux, A Dewailly, S Dharancy, A Di Fiore, D Djeddi, R Djedir, M L Dreher-Duwat, R Dubois, C Dubuque, P Ducatillon, J Duclay, B Ducrocq, F Ducrot, P Ducrotte, A Dufilho, C Duhamel, D Dujardin, C Dumant-Forest, J L Dupas, F Dupont, Y Duranton, A Duriez, K El Achkar, M El Farisi, C Elie, M C Elie-Legrand, A Elkhaki, M Eoche, D Evrard, J P Evrard, A Fatome, B Filoche, L Finet, M Flahaut, C Flamme, D Foissey, P Fournier, M C Foutrein-Comes, P Foutrein, D Fremond, T Frere, M Fumery, P Gallet, C Gamblin, P S Ganga-Zandzou, R Gérard, G Geslin, Y Gheyssens, N Ghossini, S Ghrib, T Gilbert, B Gillet, D Godard, P Godard, J M Godchaux, R Godchaux, G Goegebeur, O Goria, F Gottrand, P Gower, B Grandmaison, M Groux, C Guedon, J F Guillard, L Guillem, F Guillemot, D Guimber, B Haddouche, S Hakim, D Hanon, V Hautefeuille, P Heckestweiller, G Hecquet, J P Hedde, H Hellal, P E Henneresse, B Heyman, M Heraud, S Herve, P Hochain, L Houssin-Bailly, P Houcke, B Huguenin, S Iobagiu, A Ivanovic, I Iwanicki-Caron, E Janicki, M Jarry, J Jeu, J P Joly, C Jonas, F Katherin, A Kerleveo, A Khachfe, A Kiriakos, J Kiriakos, O Klein, M Kohut, R Kornhauser, D Koutsomanis, J E Laberenne, G Laffineur, M Lagarde, P Lannoy, J Lapchin, M Lapprand, D Laude, R Leblanc, P Lecieux, N Leclerc, C Le Couteulx, J Ledent, J Lefebvre, P Lefiliatre, C Legrand, A Le Grix, P Lelong, B Leluyer, C Lenaerts, L Lepileur, A Leplat, E Lepoutre-Dujardin, H Leroi, M Y Leroy, J P Lesage, X Lesage, J Lesage, I Lescanne-Darchis, J Lescut, D Lescut, B Leurent, P Levy, M Lhermie, A Lion, B Lisambert, F Loire, S Louf, A Louvet, M Luciani, D Lucidarme, J Lugand, O Macaigne, D Maetz, D Maillard, H Mancheron, O Manolache, A B Marks-Brunel, R Marti, F Martin, G Martin, E Marzloff, P Mathurin, J Mauillon, V Maunoury, J L Maupas, B Mesnard, P Metayer, L Methari, B Meurisse, F Meurisse, L Michaud, X Mirmaran, P Modaine, A Monthe, L Morel, P E Mortier, E Moulin, O Mouterde, J Mudry, M Nachury, N'Guyen E Khac, B Notteghem, V Ollevier, A Ostyn, A Ouraghi, D Ouvry, B Paillot, N Panien-Claudot, C Paoletti, A Papazian, B Parent, B Pariente, J C Paris, P Patrier, L Paupart, B Pauwels, M Pauwels, R Petit, M Piat, S Piotte, C Plane, B Plouvier, E Pollet, P Pommelet, D Pop, C Pordes, G Pouchain, P Prades, A Prevost, J C Prevost, B Quesnel, A M Queuniet, J F Quinton, A Rabache, P Rabelle, G Raclot, S Ratajczyk, D Rault, V Razemon, N Reix, M Revillon, C Richez, P Robinson, J Rodriguez, J Roger, J M Roux, A Rudelli, A Saber, G Savoye, P Schlosseberg, M Segrestin, D Seguy, M Serin, A Seryer, F Sevenet, N Shekh, J Silvie, V Simon, C Spyckerelle, N Talbodec, A Techy, J L Thelu, A Thevenin, H Thiebault, J Thomas, J M Thorel, G Tielman, M Tode, J Toisin, J Tonnel, J Y Touchais, Y Touze, J L Tranvouez, C Triplet, D Turck, S Uhlen, E Vaillant, C Valmage, D Vanco, H Vandamme, E Vanderbecq, Vander E Eecken, P Vandermolen, P Vandevenne, L Vandeville, A Vandewalle, C Vandewalle, P Vaneslander, J P Vanhoove, A Vanrenterghem, P Varlet, I Vasies, G Verbiese, G Vernier-Massouille, P Vermelle, C Verne, P Vezilier-Cocq, B Vigneron, M Vincendet, J Viot, Y M Voiment, A Wacrenier, L Waeghemaecker, J Y Wallez, M Wantiez, F Wartel, J Weber, J L Willocquet, N Wizla, E Wolschies, A Zalar, B Zaouri, A Zellweger, C Ziade, Hôpital Jeanne de Flandre [Lille], Lille Inflammation Research International Center - U 995 (LIRIC), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Epidémiologie et de Santé Publique [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Registre EPIMAD, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Hépato Gastroenterologie [CHU Amiens-Picardie], CHU Amiens-Picardie, Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Unité Pédiatrique [Saint-Vincent de Paul Lille], Hôpital Saint-Vincent de Paul, Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, and Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, medicine.medical_specialty, Adolescent, Population, MEDLINE, Disease, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, Internal medicine, medicine, Humans, Colitis, Child, education, ComputingMilieux_MISCELLANEOUS, Crohn's disease, education.field_of_study, Hepatology, business.industry, Incidence, Incidence (epidemiology), Gastroenterology, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Inflammatory Bowel Diseases, medicine.disease, Ulcerative colitis, digestive system diseases, 3. Good health, Population based study, 030220 oncology & carcinogenesis, Colitis, Ulcerative, Female, 030211 gastroenterology & hepatology, France, business
Abstract

Few data are available to describe the changes in incidence of pediatric-onset inflammatory bowel disease (IBD). The aim of this study was to describe changes in incidence and phenotypic presentation of pediatric-onset IBD in northern France during a 24-year period.Pediatric-onset IBD (17 years) was issued from a population-based IBD study in France between 1988 and 2011. Age groups and digestive location were defined according to the Paris classification.1,350 incident cases were recorded (8.3% of all IBD) including 990 Crohn's disease (CD), 326 ulcerative colitis (UC) and 34 IBD unclassified (IBDU). Median age at diagnosis was similar in CD (14.4 years (Q1=11.8-Q3=16.0)) and UC (14.0 years (11.0-16.0)) and did not change over time. There were significantly more males with CD (females/males=0.82) than UC (females/males=1.25) (P=0.0042). Median time between onset of symptoms and IBD diagnosis was consistently 3 months (1-6). Mean incidence was 4.4/10In this population-based study, CD and UC incidences increased dramatically in adolescents across a 24-year span, suggesting that one or more strong environmental factors may predispose this population to IBD.

Published
2018
Full Text
View/download PDF

5. Pregnancy is possible on long-term home parenteral nutrition in patients with chronic intestinal failure: Results of a long term retrospective observational study

Author

Laura Armengol Debeir, Francisca Joly, Nicolas Cury, Eric Lerebours, Emilie Latour Beaudet, Florian Poullenot, Evelyne Marinier, Pierre-François Ceccaldi, Lore Billiauws, Cécile Chambrier, Olivier Goulet, and Olivier Corcos

Subjects
Adult, Male, Risk, Short Bowel Syndrome, 0301 basic medicine, Pediatrics, medicine.medical_specialty, Referral, Pregnancy, High-Risk, Critical Care and Intensive Care Medicine, Severity of Illness Index, Cohort Studies, 03 medical and health sciences, Quality of life, Pregnancy, Humans, Medicine, Retrospective Studies, Fetal Growth Retardation, 030109 nutrition & dietetics, Nutrition and Dietetics, business.industry, Intestinal Pseudo-Obstruction, Postpartum Hemorrhage, Infant, Newborn, Retrospective cohort study, Maternal Nutritional Physiological Phenomena, medicine.disease, Short bowel syndrome, Chronic intestinal failure, Pregnancy Complications, Intestinal Diseases, Parenteral nutrition, Parenteral Nutrition, Home Total, Premature Birth, Female, France, medicine.symptom, business, Weight gain, Follow-Up Studies
Abstract

Summary Background & aims Home parenteral nutrition (HPN) improves survival and quality of life in patients with chronic intestinal failure (IF). Few cases of pregnancy on HPN have been published. The aim of this study was to report pregnancy cases on long-term HPN in benign IF. Methods This retrospective study included all pregnant patients on HPN from 4 HPN referral centers. Data on demographics, ongoing pathology, HPN type, maternal and newborn complications were collected. Results From 1984 to 2014, 21 pregnancies occurred in 15 patients (short bowel syndrome (n = 11), motility disorders (n = 3), mucosal disease (n = 1)) of whom 14 occurred after 2010. Median follow-up was 12 years. Median HPN duration before pregnancy was 8 years. HPN was adapted monthly during pregnancy, with close monitoring and supplementations. Energy intake was regularly increased and median maternal weight gain was 10 kg. Median age at the first pregnancy was 27 years. In 55% of cases, the newborn was preterm. Maternal complications occurred in 67% of cases (mainly due to underlying disease or HPN complications). There were 3 post-partum hemorrhages and 6 hypotrophic newborns. Eighteen infants were healthy and 2 chronic intestinal pseudo-obstruction (CIPO) were suspected. Conclusion Our series, the largest reported to date, shows that pregnancy is possible in HPN patients but the complication rate is high. A specific support is necessary, particularly in CIPO patients. As pregnancies have increased over the last 15 years, physicians practicing in HPN referral centers should be aware of the need for implementing a specific multidisciplinary monitoring in HPN patients considering pregnancy.

Published
2017
Full Text
View/download PDF

6. Copy number variations inDCC/18q andERBB2/17q are associated with disease-free survival in microsatellite stable colon cancer

Author

David Sefrioui, Thomas Vermeulin, France Blanchard, Caroline Chapusot, Ludivine Beaussire, Laura Armengol-Debeir, Richard Sesboué, Alice Gangloff, Mohamed Hebbar, Marie-Christine Copin, Estelle Houivet, Lilian Schwarz, Florian Clatot, Jean-Jacques Tuech, Jacques Bénichou, Laurent Martin, Anne-Marie Bouvier, Jean-Christophe Sabourin, Nasrin Sarafan-Vasseur, Thierry Frébourg, Côme Lepage, Pierre Michel, and Frédéric Di Fiore

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Colorectal cancer, Hazard ratio, medicine.disease, Bioinformatics, Confidence interval, 3. Good health, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Chromosome instability, Multiplex polymerase chain reaction, Medicine, Copy-number variation, Stage (cooking), business, Prospective cohort study
Abstract

We conducted a prospective study to assess the prognostic impact of selected copy number variations (CNVs) in stage II-III microsatellite stable (MSS) colon cancer. A total of 401 patients were included from 01/2004 to 01/2009. The CNVs in 8 selected target genes, DCC/18q, EGFR/7p, TP53/17p, BLK/8p, MYC/8q, APC/5q, ERBB2/17q, and STK6/20q, were detected using a quantitative multiplex polymerase chain reaction of short fluorescent fragment (QMPSF) method. The primary end-point was the impact of the CNVs on the 4-year disease-free survival (DFS). The recurrence rate at 4 years was 20.9%, corresponding to 14% stage II patients vs 31% stage III patients (p

Published
2017
Full Text
View/download PDF

7. Deep remission on magnetic resonance imaging impacts outcomes of perianal fistulizing Crohn’s disease

Author

Mikael Verdalle-Cazes, Marion Chambaz, Céline Savoye-Collet, Lucie Thomassin, Guillaume Savoye, Cloé Charpentier, Valérie Bridoux, Charlotte Desprez, Sébastien Grigioni, Laura Armengol-Debeir, CCSD, Accord Elsevier, Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service d'imagerie médicale [CHU Rouen], Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Université Le Havre Normandie (ULH), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA), Service de nutrition [CHU Rouen], Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Service de chirurgie digestive [CHU Rouen], Hôpital Charles Nicolle [Rouen]-Université de Rouen Normandie (UNIROUEN), Hôpital Charles Nicolle [Rouen]-CHU Rouen, Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), and Normandie Université (NU)-Université Le Havre Normandie (ULH)

Subjects
Adult, Male, Anal fistula, medicine.medical_specialty, Contrast enhancement, Adolescent, Kaplan-Meier Estimate, Disease, Perineum, Disease-Free Survival, Tertiary Care Centers, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, Gastrointestinal Agents, medicine, Humans, Rectal Fistula, In patient, Pathological, ComputingMilieux_MISCELLANEOUS, Aged, Retrospective Studies, Crohn's disease, Hepatology, medicine.diagnostic_test, Tumor Necrosis Factor-alpha, business.industry, Adalimumab, Gastroenterology, Antibodies, Monoclonal, Magnetic resonance imaging, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Middle Aged, medicine.disease, Magnetic Resonance Imaging, Infliximab, Hyperintensity, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, 3. Good health, Hospitalization, Treatment Outcome, 030220 oncology & carcinogenesis, Female, 030211 gastroenterology & hepatology, Radiology, business
Abstract

The long-term management of perianal Crohn's disease for patients on anti-TNF-α therapy remains challenging.To evaluate the long-term course and complications of patients with perianal fistulas treated with anti-TNF-α based on their clinical remission and healing on MRI.Patients were evaluated clinically and by MRI. Deep remission was defined as clinical remission associated with the absence of contrast enhancement and T2 hyperintensity on MRI. Flare-free survival, surgery and hospitalizations were compared based on the presence or not of deep remission.Forty-eight consecutive patients were included with a median follow-up of 62 months after anti-TNF-α first administration. Deep remission was observed in 16 patients (33.4%). For patients in deep remission, the median time to any perianal event was 116 months (95-130) versus 42 months (8-72) in patients with pathological MRI (p 0.001). Sixteen patients (50%) with pathological MRI had perianal surgery versus 2 (12.5%) in the deep remission group (p 0.05). The mean duration of cumulative hospital stays was 0.75 ± 0.52 days in the deep remission group versus 19.7 ± 7.4 in the pathological group (p 0.05).Higher flare-free survival and lower rates of surgery and hospitalization were found in patients achieving deep remission.

Published
2019
Full Text
View/download PDF

8. Postoperative Complications in Pediatric Inflammatory Bowel Disease

Author

Jean-Frederic Colombel, Corinne Gower-Rousseau, Dominique Turck, Hélène Sarter, Francis Vasseur, Guillaume Pineton de Chambrun, Guillaume Savoye, Eugénie Penninck, Mathurin Fumery, Jean-Louis Dupas, Laurent Peyrin-Biroulet, Eric Lerebours, and Laura Armengol-Debeir

Subjects
Male, medicine.medical_specialty, Adolescent, Population, Inflammatory bowel disease, Gastroenterology, 03 medical and health sciences, Postoperative Complications, 0302 clinical medicine, Crohn Disease, Risk Factors, Interquartile range, 030225 pediatrics, Internal medicine, medicine, Humans, Immunology and Allergy, Prospective Studies, Child, education, Prospective cohort study, education.field_of_study, business.industry, Incidence, General surgery, Incidence (epidemiology), Hazard ratio, Prognosis, medicine.disease, Ulcerative colitis, 3. Good health, Colitis, Ulcerative, Female, 030211 gastroenterology & hepatology, France, business, Follow-Up Studies, Abdominal surgery
Abstract

BACKGROUND: We describe, in a population-based cohort, the incidence of and factors associated with postoperative complications (POCs) in pediatric-onset inflammatory bowel disease. METHODS: Using the pediatric population-based EPIMAD Cohort (1988-2004), among 692 incident inflammatory bowel disease cases, 128 patients with Crohn's disease (CD) and 25 with ulcerative colitis (UC) (22%) had undergone at least 1 major abdominal surgery at a median age of 16 years [interquartile range, Q1-Q3 = 14-17]. Factors associated with POC were assessed using Cox models. RESULTS: After a median postoperative follow-up of 8 years (3-12), 76 (49.7%) patients had experienced at least 1 POC with a total of 113 complications. The frequency of severe POC (grade >2) was similar in CD and UC (28% of all complications versus 27%, P = 0.95). A total of 64 early POCs (within 30 d of surgery) were observed in 47 patients (31%), with 33 being infectious and 31 noninfectious, higher in UC than in CD (25% of patients with CD versus 60% of patients with UC, P < 0.001). Forty-nine late POCs (≥30 d) were observed in 37 patients (24%). The occurrence of late POC was similar in UC and CD. The cumulative probability of POC was 31% (95% confidence interval, 24-39) at 1 month, 46% (38-54) at 1 year, and 48% (41-57) at 5 years. Multivariate analysis found that the UC type was the only factor associated with early POC (hazard ratio = 2.9; 95% confidence interval, 1.6-5.4). CONCLUSIONS: One-half of the children with inflammatory bowel disease had experienced at least 1 POC. Only UC relative to CD was significantly associated with an increased risk of early POC.

Published
2016
Full Text
View/download PDF

9. Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn's Disease: A French Population-Based Study

Author

Benjamin Pariente, A. Leroyer, Dana Duricova, Dominique Turck, Laurent Peyrin-Biroulet, Guillaume Savoye, Guillaume Bouguen, Carole Templier, Delphine Ley, Hélène Sarter, Laura Armengol-Debeir, S. Buche, Mathurin Fumery, Corinne Gower-Rousseau, Registre EPIMAD, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), IBD clinical and research centre, ISCARE, Prague, Czech Republic, Lille Inflammation Research International Center - U 995 (LIRIC), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Service d'Epidémiologie et de Santé Publique [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Claude Huriez [Lille], CHU Lille, Service d'hépato-gastro-entérologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Division de Gastroenterologie, Hepatologie et Nutrition, Departement de Pediatrie, Hôpital Jeanne de Flandre Lille, Hôpital Jeanne de Flandre [Lille], Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service d'Hépato Gastroenterologie [CHU Amiens-Picardie], CHU Amiens-Picardie, Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Service d'hépato-gastro-entérologie [Rennes] = Gastroenterology [Rennes], CHU Pontchaillou [Rennes], Hôpital Charles Nicolle [Rouen], and Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, medicine.medical_specialty, Adolescent, Eye Diseases, Population, Inflammatory bowel disease, Skin Diseases, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, Risk Factors, 030225 pediatrics, Internal medicine, medicine, Immunology and Allergy, Humans, Prospective Studies, Age of Onset, education, Prospective cohort study, Child, ComputingMilieux_MISCELLANEOUS, Aged, Retrospective Studies, education.field_of_study, Crohn's disease, business.industry, Incidence (epidemiology), Incidence, Hazard ratio, Gastroenterology, Retrospective cohort study, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Middle Aged, medicine.disease, Prognosis, 3. Good health, 030211 gastroenterology & hepatology, Female, France, Age of onset, Joint Diseases, business, Follow-Up Studies
Abstract

Background Extraintestinal manifestations (EIM) have been associated with more severe course of inflammatory bowel disease. The aim was to study the frequency of EIM in pediatric- and elderly-onset Crohn's disease (CD) and the factors associated with EIM and their impact on long-term disease outcome. Methods Pediatric- (age at diagnosis younger than 17 years) and elderly-onset CD patients (age at diagnosis 60 years or older) from a prospective population-based registry (EPIMAD) were recruited. Data on EIM and clinical factors at diagnosis and at maximal follow-up were collected. Results We included 535 pediatric- and 370 elderly-onset patients (median age 14.5 and 69.9 years; median follow-up 11.1 and 5.9 years). Extraintestinal manifestations presented in 23.5% of childhood-onset and 4.9% of elderly-onset individuals at diagnosis, while in 29.8% and 5.9% of patients, EIM developed newly during the follow-up (hazard ration [HR] 4.4, 95% CI, 2.7-7.0, P < 0.001). The most frequently involved organ in both age cohorts, either at diagnosis or during disease course, were joints (pediatric: 11.2% and 22.6%; elderly: 3.2% and 3.5%, respectively) followed by skin (pediatric: 15.9% and 13.6%; elderly: 2.7% and 2.7%, respectively). Extraintestinal manifestations at diagnosis were associated with increased risk for corticosteroids (HR 1.42, 95% CI, 1.14-1.78 and HR 3.38, 95% CI, 1.88-6.08) and immunosuppressive therapy (HR 1.30, 95% CI, 1.02-1.65 and HR 4.24, 95% CI, 1.91-9.42), in both age populations. Conclusions Extraintestinal manifestations occurred at lower frequency in elderly-onset compared with pediatric-onset patients. In both age populations, presence of EIM at diagnosis independently increased the need for corticosteroid and immunosuppressive treatment.

Published
2018
Full Text
View/download PDF

10. DOP74 Efficacy of ustekinumab in perianal Crohn’s disease: the BioLAP multi-centre observational study

Author

Abitbol, Yoram Bouhnik, P. Seksik, A Buisson, Laurent Siproudhis, Laurianne Plastaras, Mathieu Allez, Aurelien Amiot, L Peyrin-Biroulet, Morgane Amil, Stephanie Viennot, Nina Dib, Mélanie Serrero, Lucine Vuitton, L Caillo, Stéphane Nancey, E. Chanteloup, Mathurin Fumery, Marion Simon, Maria Nachury, G Pineton de Chambrun, Sylvie Rajca, Laura Armengol-Debeir, and C Biron

Subjects
Perianal Crohn's disease, medicine.medical_specialty, business.industry, Ustekinumab, Gastroenterology, Medicine, Observational study, General Medicine, Multi centre, business, Dermatology, medicine.drug
Published
2019
Full Text
View/download PDF

12. Infection liée à la voie veineuse centrale. Prévention et traitement

Author

Monica Stetiou, Laura Armengol-Debeir, and Eric Lerebours

Subjects
Nutrition and Dietetics, Endocrinology, Diabetes and Metabolism, Internal Medicine
Abstract

Resume L’infection liee a la voie veineuse centrale reste une complication frequente et grave de la nutrition parenterale a domicile tant chez l’enfant que chez l’adulte. Le diagnostic repose sur la clinique et la mise en evidence du meme germe sur des hemocultures prelevees en peripherie et sur la voie veineuse centrale avec un differentiel de temps de pousse superieur ou egal a 120 minutes. La prevention primaire et secondaire de l’infection repose sur une connaissance des facteurs de risque d’infection liee a la voie veineuse centrale (ILVCC), l’education therapeutique du malade et de ses proches et le respect d’un protocole strict de soins par une equipe medicale et paramedicale entrainee disposant de referentiels ecrits. Des progres ont ete realises dans la prevention de l’infection par l’utilisation plus large des verrous a base de taurolidine. Les modalites du traitement curatif dependent des donnees cliniques (signes de complications locales et/ou systemiques) et du germe isole. Le maintien eventuel de la voie veineuse centrale en cas d’infection prouvee doit reposer sur une evaluation precise et repetee du rapport risque benefice en fonction du germe isole et du contexte clinique.

Published
2013
Full Text
View/download PDF

13. Incidence and Phenotype at Diagnosis of Very-early-onset Compared with Later-onset Paediatric Inflammatory Bowel Disease: A Population-based Study [1988-2011]

Author

Benjamin Pariente, Laura Armengol-Debeir, hugues Coevoet, Laurent Peyrin-Biroulet, Claire Spyckerelle, Delphine Ley, Hélène Sarter, Mathurin Fumery, Guillaume Savoye, Francis Vasseur, Dominique Turck, Emeline Bequet, Jean-Eric Laberenne, Corinne Gower-Rousseau, Hôpital Jeanne de Flandres, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Registre EPIMAD, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Lille Inflammation Research International Center - U 995 (LIRIC), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Amiens-Picardie, Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Hôpital Claude Huriez [Lille], CHU Lille, Hôpital Jeanne de Flandre [Lille], Unité Pédiatrique [Saint-Vincent de Paul Lille], Hôpital Saint-Vincent de Paul, Hôpital privé Arras les Bonnettes, Service d'Hépato-Gastroenterologie [Seclin], Centre Hospitalier de Seclin, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), and Hôpital Charles Nicolle [Rouen]-CHU Rouen

Subjects
Male, medicine.medical_specialty, Abdominal pain, paediatric, Adolescent, Population, clinical presentation, Inflammatory bowel disease, Gastroenterology, digestive system, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, Internal medicine, medicine, Humans, Prospective Studies, Registries, Age of Onset, education, Prospective cohort study, Child, education.field_of_study, business.industry, Incidence (epidemiology), Incidence, very-early-onset, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, General Medicine, medicine.disease, Inflammatory Bowel Diseases, Ulcerative colitis, digestive system diseases, 3. Good health, Phenotype, 030220 oncology & carcinogenesis, Child, Preschool, Cohort, 030211 gastroenterology & hepatology, Colitis, Ulcerative, Female, France, medicine.symptom, Age of onset, business
Abstract

Background and aims. Very-early-onset inflammatory bowel disease (VEO-IBD) is a form of IBD that is distinct from that of children with an older onset. We compared changes over time in the incidence and phenotype at diagnosis between two groups according to age at IBD diagnosis: VEO-IBD diagnosed before the age of 6, and early-onset IBD (EO-IBD) diagnosed between 6 and 16 years of age. Methods: Data were obtained from a cohort enrolled in a prospective French population-based registry from 1988 to 2011. Results: Among the 1,412 paediatric cases (

Published
2016
Full Text
View/download PDF

16. First Study in 'Real Life' on the Effect of Teduglutide at 3 Months in a Cohort of Adult Patients with Short Bowel Syndrome (SBS)

Author

Cécile Chambrier, Florian Poullenot, Didier Quilliot, Olivier Corcos, Laura Armengol-Debeir, V. Boehm, Jacques Lallemand, Stéphane M. Schneider, Alexandre Nuzzo, Philippe Beau, Julie Bataille, and Francisca Joly

Subjects
Transplantation, Pediatrics, medicine.medical_specialty, Adult patients, business.industry, Short bowel syndrome, medicine.disease, Teduglutide, chemistry.chemical_compound, chemistry, Cohort, medicine, In real life, business
Published
2017
Full Text
View/download PDF

17. Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn's disease

Author

Laura Armengol-Debeir, Cloé Charpentier, Lucie Thomassin, C. Savoye-Collet, V. Bridoux, Edith Koning, Guillaume Savoye, Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Service de Radiologie [CHU Rouen], CHU Rouen, and Service de chirurgie digestive [CHU Rouen]

Subjects
Crohn’s disease, Male, Disease, 0302 clinical medicine, Crohn Disease, ComputingMilieux_MISCELLANEOUS, Crohn's disease, medicine.diagnostic_test, Remission Induction, Gastroenterology, Antibodies, Monoclonal, General Medicine, Middle Aged, 3. Good health, C-Reactive Protein, Treatment Outcome, 030220 oncology & carcinogenesis, Female, 030211 gastroenterology & hepatology, Radiology, Adult, Anal fistula, medicine.medical_specialty, Adolescent, Observational Study, Young Adult, 03 medical and health sciences, Magnetic resonance imaging, Gastrointestinal Agents, Albumins, medicine, Humans, Rectal Fistula, In patient, Aged, Biotherapy, Tumor Necrosis Factor-alpha, business.industry, Adalimumab, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, equipment and supplies, medicine.disease, Infliximab, digestive system diseases, Anus disease/diagnosis, Multivariate Analysis, business, human activities
Abstract

AIM To evaluate the imaging course of Crohn’s disease (CD) patients with perianal fistulas on long-term maintenance anti-tumor necrosis factor (TNF)-α therapy and identify predictors of deep remission. METHODS All patients with perianal CD treated with anti-TNF-α therapy at our tertiary care center were evaluated by magnetic resonance imaging (MRI) and clinical assessment. Two MR examinations were performed: at initiation of anti-TNF-α treatment and then at least 2 years after. Clinical assessment (remission, response and non-response) was based on Present’s criteria. Rectoscopic patterns, MRI Van Assche score, and MRI fistula activity signs (T2 signal and contrast enhancement) were collected for the two MR examinations. Fistula healing was defined as the absence of T2 hyperintensity and contrast enhancement on MRI. Deep remission was defined as the association of both clinical remission, absence of anal canal ulcers and healing on MRI. Characteristics and imaging patterns of patients with and without deep remission were compared by univariate and multivariate analyses. RESULTS Forty-nine consecutive patients (31 females and 18 males) were included. They ranged in age from 14-70 years (mean, 33 years). MRI and clinical assessment were performed after a mean period of exposure to anti-TNF-α therapy of 40 ± 3.7 mo. Clinical remission, response and non-response were observed in 53.1%, 20.4%, and 26.5% of patients, respectively. Deep remission was observed in 32.7% of patients. Among the 26 patients in clinical remission, 10 had persisting inflammation of fistulas on MRI (T2 hyperintensity, n = 7; contrast enhancement, n = 10). Univariate analysis showed that deep remission was associated with the absence of rectal involvement and the absence of switch of anti-TNF-α treatment or surgery requirement. Multivariate analysis demonstrated that only the absence of rectal involvement (OR = 4.6; 95%CI: 1.03-20.5) was associated with deep remission. CONCLUSION Deep remission is achieved in approximately one third of patients on maintenance anti-TNF-α therapy. Absence of rectal involvement is predictive of deep remission.

Published
2017
Full Text
View/download PDF

18. Su1924 Incidence and Phenotype at Diagnosis in Very Early Compared to Later-Onset Pediatric Inflammatory Bowel Disease: A Population-Based Study (1988-2011)

Author

Mathurin Fumery, Claire Spyckerelle, Corinne Gower-Rousseau, Benjamin Pariente, Emeline Bequet, Hélène Sarter, Laurent Peyrin-Biroulet, Guillaume Savoye, Delphine Ley, Hugues Coevoet, Dominique Turck, and Laura Armengol-Debeir

Subjects
Pathology, medicine.medical_specialty, Hepatology, business.industry, Incidence (epidemiology), Gastroenterology, medicine.disease, Inflammatory bowel disease, Phenotype, Population based study, Internal medicine, medicine, business
Published
2016
Full Text
View/download PDF

19. Pathophysiological approach to bowel dysfunction after segmental colorectal resection for deep endometriosis infiltrating the rectum: a preliminary study

Author

Guillaume Gourcerol, Jean-Jacques Tuech, Laura Armengol-Debeir, Horace Roman, Guillaume Savoye, Céline Savoye-Collet, Anne-Marie Leroi, and Maud Vassilieff

Subjects
Adult, medicine.medical_specialty, Constipation, Endometriosis, Rectum, Constriction, Pathologic, Gastroenterology, Colonic Diseases, Postoperative Complications, Internal medicine, Intussusception (medical disorder), medicine, Humans, Digestive System Surgical Procedures, Retrospective Studies, Pain, Postoperative, medicine.diagnostic_test, business.industry, Rehabilitation, Anorectal manometry, Anastomosis, Surgical, Obstetrics and Gynecology, Middle Aged, medicine.disease, Endoscopy, Surgery, Stenosis, medicine.anatomical_structure, Rectal Diseases, Treatment Outcome, Reproductive Medicine, Female, medicine.symptom, Segmental resection, business
Abstract

background: Colorectal segmental resection is performed worldwide in a majority of women presenting with symptomatic deep endometriosis infiltrating the rectum. The aim of the present study was to investigate the pathophysiological mechanisms involved in post-operative digestive dysfunction. methods: We selected patients managed by colorectal resection for rectal endometriosis, who had developed post-operative severe constipation and whose follow up was superior to 24 months. To assess the mechanisms involved in the pathogenesis of this complaint, we performed a step-by-step work up including: low digestive tract endoscopy, colonic transit time measurement and when appropriate anorectal manometry, electromyography and defecographic evaluation. results: Five out of 25 (20%) patients, whose age ranged from 27 to 41 years, were investigated for severe post-operative terminal constipation. Four different mechanisms responsible for terminal constipation were identified: tight stenosis of the colorectal anastomosis, post-operative neurological sequelae, colonic intussusception through the colorectal anastomosis and transit constipation that developed post surgery. conclusions: Post-operative constipation is a frequent complaint in women managed by colorectal resection for rectal endometriosis. A multidisciplinary approach is mandatory as pathophysiologic mechanisms may vary and prove difficult to understand. The risk of post-operative bowel dysfunction following colorectal endometriosis must be taken into account whenever this technique is proposed in young women presenting with a benign disease such as deep endometriosis.

Published
2011

20. Su1187 Delay in Diagnosis of Crohn's Disease: Description Over Time and Identification of Associated Factors: A 21-Year Population Based Study

Author

Laura Armengol-Debeir, Hélène Sarter, Francis Vasseur, Laurent Peyrin-Biroulet, Benjamin Pariente, Guillaume Savoye, Corinne Gower-Rousseau, Dominique Turck, Mathurin Fumery, Luc Dauchet, Michael T. Collins, and Eric Laberenne

Subjects
Population based study, Pediatrics, medicine.medical_specialty, Crohn's disease, Hepatology, business.industry, Internal medicine, Gastroenterology, Medicine, Identification (biology), business, medicine.disease
Published
2015
Full Text
View/download PDF

21. 8 Receiving Corticosteroids Therapy Is Associated With a Poor Outcome in Patients With Elderly-Onset Ulcerative Colitis: A Population-Based Study

Author

Mathurin Fumery, Benjamin Pariente, hugues Coevoet, Luc Dauchet, Hélène Sarter, Eric Laberenne, Guillaume Savoye, Laurent Peyrin-Biroulet, Corinne Gower-Rousseau, Laura Armengol-Debeir, and Cloé Charpentier

Subjects
Population based study, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, Medicine, Elderly onset, In patient, business, medicine.disease, Outcome (game theory), Ulcerative colitis
Published
2015
Full Text
View/download PDF

22. Su1296 Increase of Inflammatory Bowel Disease Incidence in Teenagers in a Prospective Population-Based-Study During a 21-Year Period (1988-2008)

Author

Laurent Peyrin-Biroulet, Hélène Sarter, Silvia Ghione, Dominique Turck, Corinne Gower-Rousseau, Olivier Mouterde, Claire Spyckerelle, Guillaume Savoye, Luc Dauchet, Delphine Ley, Mathurin Fumery, Benjamin Pariente, Laura Armengol-Debeir, and Djamal-Dine Djeddi

Subjects
Population based study, Pediatrics, medicine.medical_specialty, Hepatology, business.industry, Incidence (epidemiology), Period (gene), Gastroenterology, Medicine, business, medicine.disease, Inflammatory bowel disease
Published
2015
Full Text
View/download PDF

23. Recours aux urgences des patients suivis pour une maladie de Crohn‎ : facteurs de risque et prise en charge

Author

Bénard, Coralie, UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), and Laura Armengol-Debeir

Subjects
TDM, Complications, Urgences, Hospitalisation, Chirurgie, Maladie de Crohn, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

La maladie de Crohn (MC) est une pathologie chronique à risque de complication. Le recours au service d'accueil des urgences (SAU) a considérablement augmenté ces dernières années. Les objectifs de notre étude sont d’identifier et de décrire, au sein d’une population de patients atteints de MC, suivis au CHU de Rouen, ceux ayant recours au SAU et d’en identifier les principaux facteurs de risque. Méthodes : Les patients ayant consulté pour une MC, dans le service d’Hépato-gastro-entérologie du CHU de Rouen entre novembre 2013 et novembre 2014, ont été inclus. L'analyse des données a été réalisée rétrospectivement grâce au logiciel informatique CDP2 du CHU. Résultats : Au total, 638 patients ont été inclus. Parmi eux, 49.8% (n=318) ont eu recours au moins une fois au SAU depuis le début de leur suivi au CHU. En analyse multivariée, les facteurs de risque de recours au SAU sont : la localisation iléale ou iléo colique au diagnostic (OR=1.32, p=0.04), le changement de phénotype au cours de l'évolution (OR=1.28, p=0.02) et la durée d'évolution de la maladie (OR=1.32, p=0.02). L’exposition aux antiTNFα diminue de moitié le risque de recours au SAU (OR=0.44, p

Published
2015

24. Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn's disease.

Author

Thomassin L, Armengol-Debeir L, Charpentier C, Bridoux V, Koning E, Savoye G, and Savoye-Collet C

Subjects
Adalimumab therapeutic use, Adolescent, Adult, Aged, Albumins chemistry, Antibodies, Monoclonal therapeutic use, C-Reactive Protein chemistry, Crohn Disease therapy, Female, Gastrointestinal Agents therapeutic use, Humans, Infliximab therapeutic use, Male, Middle Aged, Multivariate Analysis, Rectal Fistula therapy, Remission Induction, Treatment Outcome, Tumor Necrosis Factor-alpha antagonists & inhibitors, Young Adult, Crohn Disease diagnostic imaging, Magnetic Resonance Imaging, Rectal Fistula diagnostic imaging
Abstract

Aim: To evaluate the imaging course of Crohn's disease (CD) patients with perianal fistulas on long-term maintenance anti-tumor necrosis factor (TNF)-α therapy and identify predictors of deep remission., Methods: All patients with perianal CD treated with anti-TNF-α therapy at our tertiary care center were evaluated by magnetic resonance imaging (MRI) and clinical assessment. Two MR examinations were performed: at initiation of anti-TNF-α treatment and then at least 2 years after. Clinical assessment (remission, response and non-response) was based on Present's criteria. Rectoscopic patterns, MRI Van Assche score, and MRI fistula activity signs (T2 signal and contrast enhancement) were collected for the two MR examinations. Fistula healing was defined as the absence of T2 hyperintensity and contrast enhancement on MRI. Deep remission was defined as the association of both clinical remission, absence of anal canal ulcers and healing on MRI. Characteristics and imaging patterns of patients with and without deep remission were compared by univariate and multivariate analyses., Results: Forty-nine consecutive patients (31 females and 18 males) were included. They ranged in age from 14-70 years (mean, 33 years). MRI and clinical assessment were performed after a mean period of exposure to anti-TNF-α therapy of 40 ± 3.7 mo. Clinical remission, response and non-response were observed in 53.1%, 20.4%, and 26.5% of patients, respectively. Deep remission was observed in 32.7% of patients. Among the 26 patients in clinical remission, 10 had persisting inflammation of fistulas on MRI (T2 hyperintensity, n = 7; contrast enhancement, n = 10). Univariate analysis showed that deep remission was associated with the absence of rectal involvement and the absence of switch of anti-TNF-α treatment or surgery requirement. Multivariate analysis demonstrated that only the absence of rectal involvement (OR = 4.6; 95%CI: 1.03-20.5) was associated with deep remission., Conclusion: Deep remission is achieved in approximately one third of patients on maintenance anti-TNF-α therapy. Absence of rectal involvement is predictive of deep remission., Competing Interests: Conflict-of-interest statement: There are no conflict of interest to report.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results